Aethlon Medical, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.7M
- Price
- $6.07
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.33%
- Volume
- 28.5K
About
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Quick stats
Shares outstanding1.6M
Computed float1.6M
Float / shares99.4%
Cash runway (months)3.4
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000882291
AI Summary
AI-generated1/24
minorneutrallegal litigation
Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Aethlon Medical's proposed merger with North Immunology, Inc., under which Aethlon shareholders are expected to own approximately 4.75% of the combined company.
The same release also targets Priority Technology Holdings' $8.05-per-share cash sale to an investor group led by its own Chairman and CEO, and MISTRAS Group's $20.35-per-share cash sale to affiliates of H.I.G. Capital.
The notice is attorney advertising soliciting shareholders to contact the firm on a contingent-fee basis; it contains no new issuer disclosure or court action, so it should be treated as low-signal noise for AEMD.
Red flags
- Aethlon shareholders expected to own only approximately 4.75% of the combined company in the North Immunology merger
- PRTH sale is to an investor group led by its own Chairman and CEO, a conflict-of-interest dynamic cited by the investigating law firm